AMY MILMINE-STEIN: Open Payments
NPI 1942716725 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,140 in 57 payments from 9 companies in 2025. Trend: 2023 $754 · 2024 $1,079 · 2025 $1,140
Food & beverage: $1,140
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 18 | $440 |
| Ipsen Biopharmaceuticals, Inc | 9 | $230 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $171 |
| ABBVIE INC. | 5 | $92 |
| Madrigal Pharmaceuticals | 5 | $83 |
| Novo Nordisk Inc | 2 | $41 |
| Intercept Pharmaceuticals, Inc. | 2 | $37 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Mirum Pharmaceuticals, Inc. | 1 | $18 |
Products named: IQIRVO, XIFAXAN, MAVYRET, REZDIFFRA, Wegovy, OCALIVA, TERLIVAZ, Livmarli.
Industry payments across AZ — which companies pay providers there.
